title: Effectiveness of intraarterial administration of fasudil hydrochloride for preventing symptomatic vasospasm after subarachnoid hemorrhage.
abstract: OBJECTIVE
  We examined the effect of intraarterial administration of fasudil hydrochloride (IAFC), a Rho kinase inhibitor, for the prevention of symptomatic vasospasm after SAH by evaluating cerebral circulation.
  
  
  METHODS
  We evaluated IAFC cases of 57 sides of 38 patients (12 men and 26 women, average age 60.2 years old) diagnosed with aneurysmal subarachnoid hemorrhage (SAH) from February 2012 to November 2012. All cases were treated by clipping or coil embolization within 48 h after onset. Indication for IAFC was the existence of a spastic change on follow-up digital subtraction angiography (DSA) compared with that of onset.
  
  
  RESULTS
  Clipping was performed in 30 cases and coil embolization in 8 cases. IAFC was performed an average of 6.6 days after onset. Color gradient mapping demonstrated reduction of the circulation time after IAFC compared with before IAFC on 39 sides, no change on 15 sides, and extension on 3 sides. Average arterial circulation time before IAFC was 2.25 ± 0.57 s and after IAFC was 1.95 ± 0.55 s. IAFC significantly shortened average arterial circulation (P = 0.005). No case developed symptomatic vasospasm after IAFC.
  
  
  CONCLUSIONS
  IAFC significantly reduced the cerebral circulation time after aneurysmal SAH and might be effective for the prevention of symptomatic vasospasm.
authors.affiliation: Departments of Neurosurgery and Radiology, Aomori Prefectural Central Hospital, 2-1-1 Higashitsukurimichi, Aomori, 0308553, Japan, satsushi2002@yahoo.co.jp.
authors.forename: Atsushi
authors.initials: A
authors.lastname: Saito
authors.forename: Mizuho
authors.initials: M
authors.lastname: Inoue
authors.forename: Hiroyuki
authors.initials: H
authors.lastname: Kon
authors.forename: Shunji
authors.initials: S
authors.lastname: Imaruoka
authors.forename: Kiyoshi
authors.initials: K
authors.lastname: Basaki
authors.forename: Hiroshi
authors.initials: H
authors.lastname: Midorikawa
authors.forename: Tatsuya
authors.initials: T
authors.lastname: Sasaki
authors.forename: Michiharu
authors.initials: M
authors.lastname: Nishijima
mesh_terms: D019307:1-(5-Isoquinolinesulfonyl)-2-Methylpiperazine / Q000008:administration & dosage / Q000031:analogs & derivatives*; D015901:Angiography, Digital Subtraction; D001776:Blood Circulation Time / Q000187:drug effects; D002533:Cerebral Angiography; D002560:Cerebrovascular Circulation / Q000187:drug effects; D004621:Embolization, Therapeutic; D005260:Female; D006801:Humans; D007269:Injections, Intra-Arterial; D008297:Male; D008875:Middle Aged; D013345:Subarachnoid Hemorrhage / Q000150:complications* / Q000000981:diagnostic imaging / Q000188:drug therapy*; D013525:Surgical Instruments; D016896:Treatment Outcome; D014665:Vasodilator Agents / Q000008:administration & dosage; D020301:Vasospasm, Intracranial / Q000000981:diagnostic imaging / Q000209:etiology* / Q000517:prevention & control*
chemical_list: D014665:Vasodilator Agents; D019307:1-(5-Isoquinolinesulfonyl)-2-Methylpiperazine; C049347:fasudil